SparingVision Eyes CRISPR Promise With Intellia Ocular Pact
US Firm Takes 10% Stake Instead Of Cash Upfront
The French biotech has managed to bag a blue-chip partner to advance its ambitions to be the leading company in the ocular genomic medicine space, getting access to Intellia's CRISPR/Cas9 technology.
